Kureha Corporation

Seikagaku Corporation

Hirotaka Hoshi

Hikaru Saito

Motoyuki Uchida

Naoya Yamashita

Naoko Kunii

Chiaki Takahata

Provided is a method for suppressing the generation of diclofenac lactam from a compound represented by a formula (1) in the description, including allowing the compound of the formula (1) and a component (A) that is at least one type of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 mono-alcohol, a C2 to C3 di-alcohol, a C3 to C6 tri-alcohol, a polyalkylene glycol, a &#x3b3;-lactone, polyvinylpyrrolidone, a chlorogenic acid, and an alkyl sulfate ester, and salts thereof to coexist. A method for producing a pharmaceutical composition containing a compound represented by the formula (1) and a component (A), and a pharmaceutical composition which is a product produced thereby are also provided.

Pharmaceutical composition containing a hyaluronic acid derivative

Provided is a pharmaceutical composition for treating cancer and asthma. The object can be solved by a pharmaceutical composition comprising a siRNA molecule that directs cleavage of mRNA of mucin subtype 5 AC via RNA interference, or an antibody against mucin subtype 5AC as an active ingredient. According to the pharmaceutical composition of the present invention, diseases involving an overexpression of mucin subtype 5 AC can be treated efficiently. In particular, the pharmaceutical composition comprising a siRNA molecule of the present invention is effectively used in the treatment of a cancer, particularly pancreatic cancer. In addition, the siRNA or the antibody of the present invention can inhibit the expression or function of MUC5AC, thereby preventing or treating the symptoms of asthma effectively.

Pharmaceutical composition for treatment of cancer and asthma

Growing community of inventors

Tokyo, Japan

Hirotaka Hoshi